A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

Inclusion Criteria: * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1 * Signed Informed Consent Form * Histologically or cytologically documented, locally advanced or metastatic solid tumors or lymphoma for which standard therapy either does not exist or has proven ineffective or intolerable * Adequate hematologic and end-organ (liver and kidney) function * For female patients of childbearing potential and male patients with partners of childbearing potential, agreement by the patient that the patient and/or partner will use an effective form of contraception * Patients enrolled in certain phases must be willing to provide fresh and/or archival tumor samples Exclusion Criteria: * History of prior significant toxicity from a same class of agents as GDC-0425 or gemcitabine requiring discontinuation of treatment * Allergy, hypersensitivity or contraindication to the GDC-0425 formulation or gemcitabine * Experimental therapy or anti-cancer therapy within 4 weeks prior to the first dose of study drug treatment * Radiotherapy within 2 weeks prior to first dose of study drug treatment * More than two regimens of cytotoxic chemotherapy for the treatment of locally advanced or metastatic cancer * History of receiving high-dose chemotherapy requiring bone marrow or stem cell support * History of receiving radiation to more than 25% of bone marrow-bearing areas * Acute drug-related toxicities from previous therapies have not resolved prior to study entry, except for alopecia and mild neuropathy * Current severe, uncontrolled systemic disease (including but not limited to clinically significant cardiovascular, pulmonary, or renal disease or ongoing or active infection) excluding cancer * Significant heart disease and heart dysfunction including but not limited to uncontrolled severe hypertension, heart failure, and reduced cardiac contractility * Uncontrolled ascites, due to diseases other than cancer * Inability or unwillingness to swallow pills/capsules * History of malabsorption or other condition that would interfere with drug absorption * Any history of active stomach and/or intestine bleeding within the 6 months prior to screening * Known HIV infection * Pregnancy, lactation, or breastfeeding * Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms * Inability to comply with study and follow up procedures